Ironwood Pharmaceuticals Inc (IRWD) — Titan Protect Analysis

IRWD

Ironwood Pharmaceuticals Inc

Healthcare · ·

$3.31

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$533M

Total market value of the company

Trailing P/E

5.22

Very cheap relative to earnings

Forward P/E

2.25

Based on estimated future earnings — lower means cheaper

Rev Growth

+158.9%

Year-over-year revenue change

Profit Margin

28.3%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.35

+62% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA name

https://ironwoodpharma.com

Country: United States Employees: 100 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.220

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0201

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.296

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-27.2%

Historical annualised return based on price data

Max Drawdown

-91.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

105

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.30

Very low correlation to market moves

52W High

$5.78

43% below the year high

52W Low

$0.56

491% above the year low

Avg Volume

2,499,331

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.62

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

75.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

68.1%

Profit from core operations before interest and tax

Free Cash Flow

$51M

Positive — the business generates more cash than it spends

Revenue (TTM)

$362M

Total revenue over the last 12 months

Net Income

$102M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$5.35

Target Low

$3.70

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go